Sino Biological and BioGeometry deepen strategic collaboration to strengthen protein research and development with generative AI

Sino Biological and BioGeometry deepen strategic collaboration to strengthen protein research and development with generative AI

Sino Biological, a leading recombinant protein production company, is pleased to announce an expansion of its strategic partnership with BioGeometry, a digital biology pioneer. This collaboration combines Sino Biological's advanced protein expression and wet lab capabilities with BioGeometry's generative AI platform for protein design and optimization. The aim of the two companies is to expand their joint offerings and explore high-value market opportunities worldwide.

Sino Biological is committed to driving innovation in bioproduction by integrating state-of-the-art technologies. The company's expertise in protein and antibody research, combined with BioGeometry's breakthroughs in generative AI, provides unparalleled solutions for protein design and optimization. This partnership is expected to significantly accelerate the pace of discovery for researchers and pharmaceutical companies and provide customers with access to faster and more efficient protein R&D services.

Deep learning, particularly large-scale generative AI models, is revolutionizing bioproduction. AlphaFold3 can now use diffusion models to predict the structure of biomolecules, significantly advancing protein design. BioGeometry, a leader in generative AI for protein design, pioneered diffusion models with its influential 2021 “GeoDiff” paper. In June, BioGeometry introduced GeoFlow, a basic protein model that excels in structure prediction and design and competes with AlphaFold3 in predicting antigen-antibody complexes. GeoFlow is available free for non-commercial use and is integrated into BioGeometry's GeoBiologics platform, improving the efficiency of protein design with fewer experiments.

The partnership between Sino Biological and BioGeometry to combine generative AI with wet lab experiments provides advanced research tools and CRO services. Their collaboration leverages BioGeometry's GeoFlow-based platform and Sino Biological's protein expression capabilities to improve design efficiency and accuracy. By updating AI models with experimental data, they accelerate project completion. They have already successfully developed nanobodies and enzymes and want to further innovate AI-driven protein research, contributing to advances in biopharmaceuticals, disease treatment and sustainable development.

Sino Biological has long been known for its comprehensive CRO technical services platform, which includes gene cloning, protein expression, antibody development and quality control research. With capabilities ranging from gene sequencing to large-scale production, Sino Biological provides preclinical manufacturing services at unprecedented speed, producing purified monoclonal antibodies in just weeks. The company's extensive protein and antibody library, as well as its extensive screening and production platforms, position Sino Biological as a global leader in life science research and innovative drug development.

Looking forward, Sino Biological and BioGeometry will continue to explore new applications of AI in protein research and development, aiming to shape the future of biopharmaceutical research and development and make significant contributions to disease treatment and sustainable scientific progress.

Sources: